Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway

KIORA PHARMACEUTICALS INC

Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.
Cash, equivalents and short-term investments of $17.1M as of Dec 31, 2025; expects runway into late 2027.
KIO-301 Phase 2 ABACUS-2 trial for retinitis pigmentosa advancing; initial data readout expected Q3 2027.
KIO-104 Phase 2 KLARITY trial for macular edema dosing; non-cash impairment charge in Q4.
Executed option agreement with Senju for KIO-301 in Asia with potential value up to $110M plus royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.